Autophagy-Lysosome Pathway in Multiple System Atrophy Pathogenesis: The Best Is Yet to Come

Area of Science:

• Neuroscience
• Cell Biology
• Pathology

Background:

• Alpha-Synucleinopathies, including Parkinson's disease (PD) and Multiple System Atrophy (MSA), are characterized by the accumulation of alpha-Synuclein protein aggregates.
• The autophagy-lysosome pathway (ALP) is crucial for cellular protein degradation, and its dysfunction is implicated in neurodegenerative diseases.
• Genetic links between lysosomal dysfunction (e.g., GBA1 mutations) and PD pathogenesis are established, with emerging evidence in MSA.

Purpose of the Study:

• To review the pathological features of MSA, focusing on alpha-Synuclein accumulation.
• To examine the impairments within the autophagy-lysosome pathway (ALP) associated with MSA.
• To discuss current challenges and future therapeutic strategies targeting autophagy in experimental MSA models.

Main Methods:

• Literature review of human post-mortem brain studies, cellular models, and animal models of alpha-Synucleinopathies.
• Analysis of data on histopathological hallmarks and protein aggregation in PD and MSA.
• Examination of research on the role of the autophagy-lysosome pathway in the pathogenesis of MSA.

Main Results:

• Alpha-Synuclein accumulation in neurons (PD) or oligodendrocytes (MSA) is a key histopathological feature.
• Evidence suggests altered components of the autophagy-lysosome pathway in alpha-Synucleinopathies, impacting alpha-Synuclein degradation.
• Lysosomal dysfunction, linked to GBA1 mutations in PD, shows correlative increases in alpha-Synuclein deposition, with less extensive data available for MSA.

Conclusions:

• The autophagy-lysosome pathway is critically involved in MSA pathogenesis, alongside alpha-Synuclein accumulation.
• Understanding ALP impairments in MSA is essential for developing targeted therapeutic interventions.
• Further research into experimental MSA models is needed to explore autophagy-targeting strategies.